Boardroom Alpha
Boardroom Alpha
COCH · Additional Proxy Materials (DEFA14A) · Filed April 2, 2026

Envoy Medical Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 2, 2026
Ticker
COCH
Accession
0001213900-26-039313
Boardroom Alpha · Filing insights

Envoy Medical seeks two Class III directors; board urges votes for all listed proposals, including pay and equity amendments.

About Envoy Medical Inc
Market cap
$54M
1Y TSR
−52.6%
3Y TSR
−59.2%
Board grade
C-
Sector
Healthcare
CEO
Brent T Lucas
Last annual meeting: May 12, 2026 · View full Envoy Medical Inc profile →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

––––––––––––––––––––––––––––––––––

SCHEDULE 14A

––––––––––––––––––––––––––––––––––

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant

 

Filed by a Party other than the Registrant

 

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under §240.14a-12

Envoy Medical, Inc.

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

(Name of Registrant as Specified In Its Charter)

–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

  

 

 

CONTROL ID:

REQUEST ID:

 

ENVOY MEDICAL, INC

   
           

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS
for the Annual Meeting of Stockholders

 

DATE:

Tuesday, May 12, 2026

 
 

TIME:

3:00 PM Central Time

   
 

LOCATION:

60 South Sixth Street, Suite 1500, Minneapolis, MN 55402

           

HOW TO REQUEST PAPER COPIES OF OUR MATERIALS

PHONE: 
Call toll free 
1-866-752-8683

FAX: 
Send this card to 
202-521-3464

INTERNET:
https://www.iproxydirect.com/Coch
and follow the on-screen
instructions
.

EMAIL:
Proxy-ID@equinity.com
Include your Control ID in your
email.

           

This communication represents a notice to access a more complete set of proxy materials available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement is available at: https://www.iproxydirect.com/COCH

If you want to receive a paper copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request, as instructed above, before April 28, 2026

you may enter your voting instructions at https://www.iproxydirect.com/COCH
until 11:59 pm eastern time May 11, 2026.

   

The purposes of this meeting are as follows:

1.     To elect two Class III director nominees named in the Proxy Statement to the Envoy Medical Board of Directors, to serve a term that continues until the 2029 annual meeting of stockholders;

2.     To ratify the appointment of EisnerAmper LLP as Envoy Medical’s independent registered public accounting firm for the year ending December 31, 2026;

3.     To approve, on an advisory basis, the Company’s named executive officer (NEO) compensation;

4.     To approve an amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan;

5.     To approve an amendment to the Envoy Medical, Inc. 2023 Employee Stock Purchase Plan;

6.     To approve, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of warrants to purchase shares of the Company’s Class A Common Stock, par value $0.0001 (“Class A Common Stock”), and the issuance of Class A Common Stck underlying such warrants, that were issued in a transaction that was completed on February 12, 2026; and

7.     To transact any other business as may properly come before the meeting or any adjournments thereof, including matters incident to the conduct of the meeting.

Pursuant to Securities and Exchange Commission rules, you are receiving this Notice that the proxy materials for the Annual Meeting are available on the Internet. Follow the instructions above to view the materials and vote or request printed copies.

The board of directors has fixed the close of business on March 16, 2026 as the record date for the determination of stockholders entitled to receive notice of the Annual Meeting and to vote the shares of our Class A common stock, par value $0.0001 per share, they held on that date at the meeting or any postponement or adjournment of the meeting.

The Board of Directors recommends that you vote ‘for’ all proposals above.

Please note — This is not a Proxy Card — you cannot vote by returning this card

 

       
         

ENVOY MEDICAL, INC
C/O ISSUER DIRECT COMPLIANCE
1110 CENTRE POINT CURVE STE 101
MENDOTA HEIGHTS MN 55120

     

FIRST-CLASS MAIL  
US POSTAGE
PAID
DURHAM NC
PERMIT # 302

         

Time Sensitive shareholder information enclosed

IMPORTANT SHAREHOLDER
INFORMATION

your vote is imporant

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Envoy Medical Inc (COCH)

Reference

Frequently asked questions

When did Envoy Medical Inc file this DEFA14A?
Envoy Medical Inc (COCH) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 2, 2026. The accession number assigned by EDGAR is 0001213900-26-039313.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Envoy Medical seeks two Class III directors; board urges votes for all listed proposals, including pay and equity amendments. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Envoy Medical Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Envoy Medical Inc has filed under CIK 1840877, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer